Carbapenem-resistant Enterobacteriaceae (CRE) are extensively drug resistant organisms (XDROs) that have few treatment options and high mortality rates. CRE are increasingly detected among patients in Illinois, including in acute and long term care healthcare facilities.
In response to the CRE public health threat, the Illinois Department of Public Health (IDPH) has guided development of an infection control tool called the XDRO registry. The purpose of the XDRO registry is two-fold:
- Improve CRE surveillance: The first CRE-positive culture per patient stay must be reported to the XDRO registry.
- Improve inter-facility communication: Healthcare facilities can query the XDRO registry to see whether a patient has been previously reported as CRE-positive.
For access to the XDRO registry, click here
UPDATES
- As of June 2019, IDPH is entering carbapenemase-producing Acinetobacter baumannii cases into the XDRO registry. Link: [CDC Acinetobacter in Healthcare Settings]
- As of April 2017, IDPH is entering carbapenemase-producing Pseudomonas aeruginosa cases into the XDRO registry. Link: [CDC Pseudomonas aeruginosa in Healthcare Settings]
- As of January 2017, IDPH is entering Candida auris cases into the XDRO registry. Links: [CDC C. auris Questions and Answers][CDC C. auris main page]
- IL CRE Detect and Protect Campaign. More...
- CRE are reportable to IDPH via the XDRO registry. Links: [IDPH letter to facilities, September 2013][Reporting rule]
- XDRO registry orientation webinar [Slides][Recording]
- CDC guidance on control of CRE: [Toolkit]
- AHRQ CRE Toolkit: [Carbapenem-Resistant Enterobacteriaceae (CRE) Control and Prevention Toolkit]
- As of November 1, 2013, the XDRO registry is open for CRE submissions and queries.
View FAQs: [FAQs PDF]